Background: This paper reports the proceedings of the European Advisory Panel Meeting for tazarotene (Zorac™), which took place in Cologne on May 7, 1998. Aim: The aim of this meeting was to discuss recommendations for the use of tazarotene based on the clinical data available and on the clinical experience of the Advisory Panel members, and to identify future research needs. Recommendations: Based on currently available data, tazarotene can be used for the treatment of chronic, stable, plaque-type psoriasis, on the trunk or limbs covering up to 20% of the body surface area. In clinical trials, patients generally experienced a clinical response within 4 weeks of starting tazarotene treatment, and improvement was maintained for up to 12 weeks after stopping therapy. Results from published and not yet published clinical trials show that the efficacy and tolerability of tazarotene can be enhanced by the addition of topical corticosteroids to the treatment regimen and that, when used in combination with broad-band UVB phototherapy, tazarotene reduces the amount of UV light required to treat plaques. Tazarotene gel is available in two concentrations, 0.05 and 0.1%. The Advisory Panel recommends that the choice of concentration should be based on factors such as the irritability of the patient’s skin and the thickness of plaques. Irritation can be managed by reducing the concentration or frequency of application, or by adding a topical corticosteroid to therapy. Tazarotene shows promise as a treatment for psoriasis in special localisations, such as the scalp, face and skin folds, although clinical studies are required.

Gollnick HPM: Oral retinoids – Efficacy and toxicity in psoriasis. Br J Dermatol 1996;135: 6–17.
Fisher GJ, Talwar HS, Xiao JH, Datta SC, Reddy AP, Gaub MP, Rochette-Egly C, Chambon P, Voorhees JJ: Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 1994;269:20629–20635.
Chandraratna RAS: Tazarotene – First of a new generation of receptor-selective retinoids. Br J Dermatol 1996;135:18–25.
Matsumoto RM, Sun H, Tang-Lui D: Species correlation of AGN 190168 disposition in mouse, hamster, rat, rabbit, monkey and man. Pharm Res 1992;9(suppl):274.
Nagpal S, Athanikar J, Chandraratna RAS. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor α. J Biol Chem 1995;270:923–927.
Halkier-Sorenson L, Laurberg G, Andresen J: Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987;16:999–1006.
Geiger JM, Baudin M, Saurat JH: Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994;189:109–116.
Marks R: Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol 1997;37:S25–S32.
Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, Jorizzo JL, Shmunes E, Tschen EH, Lew-Kaya DA, Lue JC, Sefton J, Gibson JR, Chandraratna RAS: Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85–92.
Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, Lew-Kaya DA, Lue JC, Sefton J, Chandraratna RAS: The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57–60.
Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, Wolf DI, Quell JM, Sefton J, Lue JC, Gibson JR, Chandraratna RAS: Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705–711.
Lebwohl BG, Breneman DL, Goffe SB, Grossman JR, Ling MR, Milbauer J, Pincus SH, Swinyer LJ, Weinstein GD, Lew-Kaya DA, Lue JC, Gibson JR, Sefton J: Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39:590–596.
Koo JY: Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998;39:S144– 148.
Gollnick H, Menter A: Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;140(suppl 54):18–23.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.